RARB and neoplasm: CDH13 negatively controls tumour growth and invasiveness and promotes tumour neovascularization [45], while RARβ is required for the tumour suppressive effects of retinoids [46] and RASSF1A, a key player in the Hippo tumour suppressor pathway, has roles in cell cycle regulation, apoptosis and microtubule stability [47].